Remodulin® (treprostinil sodium) Injection
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Critical Limb Ischemia
Conditions
Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
Trial Timeline
Feb 1, 2003 → Sep 1, 2004
NCT ID
NCT00060996About Remodulin® (treprostinil sodium) Injection
Remodulin® (treprostinil sodium) Injection is a phase 3 stage product being developed by United Therapeutics for Critical Limb Ischemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00060996. Target conditions include Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00060996 | Phase 3 | Terminated |
Competing Products
13 competing products in Critical Limb Ischemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin | Merck | Approved | 85 |
| Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose | Merck | Phase 1 | 33 |
| Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months. | Amgen | Approved | 84 |
| intensive insulin therapy to maintain normoglycemia | Novo Nordisk | Phase 2 | 51 |
| Midazolam + Dexmedetomidine | Pfizer | Pre-clinical | 22 |
| Apixaban + ASA + Clopidogrel 75mg | Pfizer | Phase 3 | 76 |
| Colchicine (Colcrys®) + placebo + allopurinol | Regeneron Pharmaceuticals | Approved | 84 |
| Rilonacept 80 mg + Rilonacept 160 mg | Regeneron Pharmaceuticals | Phase 3 | 76 |
| treprostinil dienthanolmine sustained release + Placebo | United Therapeutics | Phase 2 | 49 |
| Olimel (5.7%E / N9E) | Baxter | Phase 3 | 74 |
| Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Baxter | Approved | 82 |
| RJX + Placebo | ICON plc. | Phase 1 | 30 |
| Ixmyelocel-T | Vericel | Phase 3 | 72 |